WallStSmart

Aclarion Inc (ACON)vsHealthEquity Inc (HQY)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HealthEquity Inc generates 1716934% more annual revenue ($1.34B vs $77,880). HQY leads profitability with a 17.2% profit margin vs 0.0%. HQY earns a higher WallStSmart Score of 66/100 (B-).

ACON

Avoid

29

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 6.8
Piotroski: 3/9Altman Z: 2.53

HQY

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 7.5Value: 6.7Quality: 7.8
Piotroski: 7/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACON.

HQYUndervalued (+49.2%)

Margin of Safety

+49.2%

Fair Value

$151.32

Current Price

$88.67

$62.65 discount

UndervaluedFair: $151.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACON1 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

HQY2 strengths · Avg: 8.0/10
Operating MarginProfitability
29.3%8/10

Strong operational efficiency at 29.3%

EPS GrowthGrowth
34.4%8/10

Earnings expanding 34.4% YoY

Areas to Watch

ACON4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$8.27M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

HQY1 concerns · Avg: 4.0/10
P/E RatioValuation
33.1x4/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ACON

The strongest argument for ACON centers on Price/Book. Revenue growth of 11.3% demonstrates continued momentum.

Bull Case : HQY

The strongest argument for HQY centers on Operating Margin, EPS Growth. Profitability is solid with margins at 17.2% and operating margin at 29.3%. PEG of 1.27 suggests the stock is reasonably priced for its growth.

Bear Case : ACON

The primary concerns for ACON are EPS Growth, Market Cap, Profit Margin.

Bear Case : HQY

The primary concerns for HQY are P/E Ratio.

Key Dynamics to Monitor

ACON profiles as a value stock while HQY is a mature play — different risk/reward profiles.

ACON carries more volatility with a beta of 1.19 — expect wider price swings.

ACON is growing revenue faster at 11.3% — sustainability is the question.

HQY generates stronger free cash flow (97M), providing more financial flexibility.

Bottom Line

HQY scores higher overall (66/100 vs 29/100), backed by strong 17.2% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aclarion Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Aclarion Inc (ACON) is a pioneering healthcare technology company that specializes in non-invasive diagnostics, focusing on musculoskeletal conditions through innovative imaging and advanced data analytics. By harnessing machine learning, Aclarion provides healthcare professionals with actionable insights that enhance clinical outcomes while optimizing costs within treatment pathways. Positioned at the vanguard of the digital health transformation, Aclarion is poised to meet the increasing demand for effective diagnostic solutions, significantly enhancing the standard of patient care in an evolving healthcare landscape. Its commitment to improving patient management establishes Aclarion as a key player in the future of healthcare delivery.

Visit Website →

HealthEquity Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

HealthEquity, Inc. provides technology-enabled service platforms to consumers and employers in the United States. The company is headquartered in Draper, Utah.

Want to dig deeper into these stocks?